Lucy Yang, Phd Email & Phone Number

Japan

Seattle, Washington, United States

• Provide expertise and hands-on support for non-viral cell therapy platform development, from R&D to PD to clinical, utilizing electroporation on immune cells, iPSCs, other primary cells, & cell lines• Collaborate closely with 30+ academic & industry clients in the Pacific NW, SF Bay Area, & W. Canada• Proficient in fragile primary cell transfections, protein production applications (expiCHO, HEK), gene editing workflows (CRISPR/RNP KO, AAV KI, HDR template KI, mRNA CARs, base editing), cGMP-oriented closed process needs

Seattle, Washington, United States

• Leading initiative to discover and characterize aptamers that bind SARS-CoV-2 spike protein, resulting in 2 first-author publications, and 1 first-author paper and 1 provisional patent in progress• Applying aptamers to therapeutics and COVID-19 rapid diagnostics, such as antibody-free ELISAs, aptamer-based lateral flow devices, and real-time aptamer-based electrochemical sensing• Mentoring undergrad student, who contributed as co-author on two publications and was awarded the Mary Gates Research Scholarship, and other lab members on assays (RT-qPCR, BLI, NGS, etc.)• Collaborating with six research groups for SARS-CoV-2 aptamer characterization and applications• Acquired 2yrs of NIH funding from the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative• Investigating targeted polymer-drug conjugates in anti-fibrotic chronic kidney disease (CKD) therapy• Conducting cell studies to show reduction of TGFB1-induced EMT by drugs and histology studies to study effect of drug delivery on kidney fibrosis in antibody-induced CKD animal models• Establishing and documenting new procedures (nanoparticle synthesis, LFA, IHC, etc.) for the lab• Designing aesthetically-pleasing, concise scientific illustrations for lab publications and grants• Developed polymeric gene delivery vehicle targeting neural progenitor cells in traumatic brain injury

Cambridge, Massachusetts, United States

• Performed single-cell analysis of cell biophysical properties for measuring mitotic growth in multiple cell lines and effect of drug inhibition on cell growth, leading to a co-authored publication in eLife• Constructed and optimized a microfluidic platform for sorting cells by morphology and incubating for organoid outgrowth studies (using LabVIEW, R, Python, laser cutting, and microscopy hardware)• Measured effect of drug treatments on cancer cell mass accumulation rate using a serial suspended microchannel resonator, resulting in co-authorship on Cancer Research publication

Kyoto, Japan

• Developed extracellular nanovesicle-based ribonucleoprotein CRISPR-Cas9 delivery platform system for exon skipping in Duchenne muscular dystrophy patient induced pluripotent stem cells• Presented findings to all scientists at the CiRA Institute, co-authored publication in Nature Communications, and contributed data that helped win a ~$600,000 3yr grant from Japan’s AMED

Koch Institute For Integrative Cancer Research

• Investigated circulating tumor cells (CTCs) dynamics through microfluidic capture of cells from live animals• Optimized LabVIEW and hardware of single-cell sorter device for efficient, clean CTC capture • Applied device to longitudinal animal studies to monitor and capture CTCs for sequencing• Led to co-authored publication in PNAS

Shanghai City, China

• Led project on engineering copolymer PEI-PEG-KALA to deliver shRNA to lung carcinoma cells

David H. Koch Institute For Integrative Cancer Research

• Engineered viral protein p19 to deliver therapeutic siRNA to tumors, led to co-authorship in NAR

The Royak Group

Bachelor Of Science (B.S.), Bioengineering

Activities and Societies: Archery Club (president), Pokémon League (founder), East Campus dormitory (treasurer, hall chair)

Doctor Of Philosophy - Phd, Bioengineering And Biomedical Engineering

Education record